Description

27,69,000 equity shares of Venmax Drugs And Pharmaceuticals Ltd listed on BSE with effect from December 30, 2025, issued on preferential basis pursuant to conversion of warrants.

Summary

BSE has announced the listing of 27,69,000 new equity shares of Venmax Drugs And Pharmaceuticals Ltd (Scrip Code: 531015) with effect from Tuesday, December 30, 2025. These shares were issued at a premium of Rs. 10/- to non-promoters on a preferential basis pursuant to the conversion of warrants. The shares rank pari-passu with existing equity shares and are subject to lock-in until July 13, 2026.

Key Points

  • Total new shares listed: 27,69,000 equity shares of Rs. 10/- each
  • Issue price: Rs. 20/- (face value Rs. 10/- + premium Rs. 10/-)
  • Issued to: Non-promoters on preferential basis
  • Basis: Conversion of warrants
  • ISIN: INE154G01022
  • Scrip Code: 531015
  • Trading commencement: December 30, 2025
  • Shares rank pari-passu with existing equity shares
  • All shares subject to lock-in until July 13, 2026

Regulatory Changes

No regulatory changes announced in this circular.

Compliance Requirements

  • Trading members are informed to note the listing of new securities
  • Lock-in restrictions apply to all 27,69,000 shares (Dist. Nos. 5238931-8007930) until July 13, 2026
  • Shares cannot be transferred or sold before the lock-in expiry date

Important Dates

  • August 16, 2025: Allotment of 20,55,000 shares (Dist. Nos. 5238931-7293930)
  • August 30, 2025: Allotment of 3,60,667 shares (Dist. Nos. 7293931-7654597)
  • September 16, 2025: Allotment of 3,53,333 shares (Dist. Nos. 7654598-8007930)
  • December 29, 2025: Notice date
  • December 30, 2025: Effective date for trading commencement
  • July 13, 2026: Lock-in expiry date for all shares

Impact Assessment

Market Impact: Low. This is a routine listing notification for a single company’s preferential allotment. The total number of shares (27.69 lakhs) represents a capital infusion from warrant conversion.

Operational Impact: Minimal. Trading members need to update their systems to recognize the new shares with appropriate lock-in restrictions.

Investor Impact: The lock-in period until July 13, 2026 ensures that non-promoter allottees cannot immediately exit, providing price stability. The preferential issue at Rs. 20/- provides information on recent valuation for existing and potential investors.

Liquidity Impact: Neutral to slightly positive. While 27.69 lakh new shares are added to the equity base, the lock-in restricts their tradability for approximately 6-7 months, limiting immediate float expansion.

Impact Justification

Routine listing of new shares from warrant conversion for a single company with lock-in restrictions; limited market-wide impact.